Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 331-336

  Korst, Annelies E C ^a   Van Der Sterre, Marianne L T ^a   Gall, Helen E ^a   Fichtinger Schepman, Anne Marie J ^b   Vermorken, Jan B ^a   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; CREATININE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DNA ADDUCT; DNA DRUG COMPLEX; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA ADDUCTS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEMOFILTRATION; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASMS; PLATINUM; RADIATION-PROTECTIVE AGENTS;

EID: 0031938492     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ozols, R. Cisplatin dose intensity. Semin. Oncol., 16: 22-30, 1989.
2. Jordan, S. W., Yuhas, J. M., and Glick, J. Modulation of cisplatinum renal toxicity by the radioprotective agent WR-2721. Exp. Mol. Pathol., 36: 297-305, 1982.
3. Yuhas, J. M., and Culo, F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat. Rep., 64: 57-64, 1980.
4. Yuhas, J. M., Spellman, J. M., Jordan, S. W., Pardini, M. C., Afzal, S. M. J., and Culo, F. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum(II) or cyclophosphamide. Br. J. Cancer, 42: 574-585, 1980.
5. Treskes, M., Boven, E., Holwerda, U., Pinedo, H. M., and Van der Vijgh, W. J. F. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res., 52: 2257-2260, 1992.
6. Glover, D., Glick, J. H., Weiler, C., Fox, K., Turrisi, A., and Kligerman, M. M. Phase I/II trials of WR-2721 and cis-platinum. Int. J. Radiat. Oncol. Biol. Phys., 12: 1509-1512, 1986.
7. Glover, D., Glick, J. H., Weiler, C., Fox, K., and Guerry, D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J. Clin. Oncol., 5: 574-578, 1987.
8. Glover, D., Grabelsky, S., Fox, K., Weiler, C., Cannon, L., and Glick, J. Clinical trials of WR-2721 and cis-platinum. Int. J. Radiat. Oncol. Biol. Phys., 16: 1201-1204, 1989.
9. Kemp, G., Rose, P., Lurain, J., Berman, R., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., and Glick, J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol., 7: 2101-2112, 1996.
10. Planting, A. S. T., Vermorken, J. B., Catimel, G., et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Proc. Am. Soc. Clin. Oncol., 15: 314, 1996.
11. Rose, P., Kemp, G., and Glick, F. Ethyol (amifostine) protects against cumulative cisplatin toxicities. Proc. Am. Soc. Clin. Oncol., 15: 533, 1996.
12. Korst, A. E. C., Boven, E., Van der Sterre, M. L. T., Fichtinger-Schepman, A. M. J., and Van der Vijgh, W. J. F. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Br. J. Cancer, 75: 1439-1446, 1997.
13. Korst, A. E. C., Van der Sterre, M. L. T., Eeltink, C. M., Fichtinger-Schepman, A. M. J., Vermorken, J. B., and Van der Vijgh, W. J. F. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. Clin. Cancer Res., 3: 697-703, 1997.
14. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
15. Fichtinger-Schepman, A. M. J., Van Oosterom, A. T., Lohman, P. H. M., and Berends, F. cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunocytochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res., 47: 3000-3004, 1987.
16. Fichtinger-Schepman, A. M. J., Van Dijk-Knijnenburg, H. C. M., and Van der Velde-Visser, S. D. Cisplatin- and carboplatin-DNA adducts: is Pt-AG the cytotoxic lesion? Carcinogenisis (Lond.), 16: 2447-2453, 1995.
17. Vermorken, J. B., Van der Vijgh, W. J. F., Klein, I., Hart, A. A. M., Gall, H. E., and Pinedo, H. M. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat. Rep., 68: 505-513, 1984.
18. Vermorken, J. B., Van der Vijgh, W. J. F., Klein, I., and Gall, H. E. Pharmacokinetics of free and total platinum species after rapid and prolonged infusion of cisplatin. Clin. Pharmacol. Ther., 39: 136-144, 1986.
19. Van der Vijgh, W. J. F. Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet., 21: 242-261, 1991.